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Abstract
Reactive oxygen species (ROSs) play important physiological and physiopathological 
roles in the cardiovascular system. An imbalance between ROS and antioxidants, termed 
oxidative stress, can contribute to endothelial dysfunction and cardiovascular remodel-
ing. ROSs have been demonstrated to be increased and to regulate the following main 
pulmonary vasculature changes that occur at high altitude (hypobaric hypoxia): hypoxic 
pulmonary vasoconstriction (HPV), pulmonary hypertension, right ventricular hyper-
trophy (RVH), and ultimately, cardiac failure. Thus, ROS increases are a public health 
concern for the increasing number of people living or working at high altitudes. ROSs 
trigger the activation of different metabolic signaling pathways that alter the activity of 
redox-sensitive transcription factors and translational signals. Consequently, we provide 
a comprehensive review of the literature on the main factors, sources, and mechanisms 
of action of ROS and their effects on the cardiovascular system under hypobaric hypoxic 
conditions. Although ROS generation is a normal physiological activity, under hypo-
baric hypoxia (high altitude) conditions, ROS levels are elevated. The principal sources 
of ROS are nicotinamide adenine dinucleotide phosphate (NADPH) oxidase-4 (NOX4) in 
the vascular system and NOX2 in cardiac tissue. Thus, the information presented in this 
review provides a broad view of the relationship between ROS and hypoxia.
Keywords: reactive oxygen species, altitude, hypoxia, cardiovascular system, 
pulmonary hypertension, right ventricle hypertrophy
1. Introduction
In the cardiovascular system, reactive oxygen species (ROSs) and reactive nitrogen species (RNSs) 
play important physiological roles in the control of endothelial functions, vascular tone, and 
cardiac functions, as well as a pathophysiological role in inflammation, hypertrophy,  fibrosis, 
© 2018 The Author(s). Licensee IntechOpen. This chapter is distributed under the t rms of the Crea ive
Comm ns Attribution Lic nse (http://creativecommons.org/licenses/by/3.0), which permits unrestricted use,
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angiogenesis, cell proliferation, apoptosis, and migration. The regulation of this biological activ-
ity is the result of a balance between oxidants and the buffering action of antioxidants, such 
that an imbalance between ROS or RNS and antioxidants (called “oxidative stress”), wherein 
ROS or RNS is increased, contributes to cellular signaling that leads to endothelial dysfunc-
tion and cardiovascular remodeling. On the one hand, ROS triggers the activation of different 
cellular pathways by activating specific proteins (e.g., Akt1/2: serine/threonine protein kinase; 
PKC: protein kinase C; PDK: 3-phosphoinositide-dependent kinase; Erk1/2: extracellular signal-
regulated kinase; JNK: c-Jun N-terminal kinase; PI3K: phosphatidylinositol-3-kinase; and JAK: 
Janus kinase) in different tissues. On the other hand, ROSs alter the activity of redox-sensitive 
transcription factors (i.e., AP-1: activator protein 1; NF-κB: nuclear factor-κB; HIF-1α: hypoxia-
inducible factor-1α; and STAT: signal transducer and activator of transcription) to induce direct 
effects on enzymes, receptors, or ion channels and different cellular responses [1]. Oxidative 
stress is generated by external factors, such as a decrease in the partial pressure of oxygen (PO
2
) 
in hypobaric hypoxia due to high-altitude exposure. Over 100 million people live in hypoxic 
conditions worldwide [2, 3], the number of people exposed to hypoxic conditions is higher if 
we include people traveling to high altitudes for either leisure or work. Human beings, except 
Tibetans, are not naturally adapted or genetically equipped to live at high altitudes. Therefore, 
depending upon its degree and duration or the altitude, hypoxia generates several physiological 
or pathological effects on the human body [4].
The main effects of exposure to hypobaric hypoxia are excessive erythrocytosis and high-alti-
tude pulmonary hypertension (HAPH). Features of the latter include high pulmonary artery 
pressure, vascular remodeling of pulmonary arteries, right ventricle hypertrophy (RVH), and 
cardiac failure. In addition to the mechanical explanation usually considered for this phenom-
enon, new data suggest other, mechanical-independent mechanisms. We attempt to provide 
a comprehensive review of the principal factors, sources, and mechanism of action of ROS in 
the development of cardiovascular diseases under hypobaric hypoxia and/or similar stress-
ors, with a specific focus on the cardiovascular system.
2. High altitude (hypobaric hypoxia) and oxidative stress 
considerations
2.1. ROS and RNS
ROSs are small molecules that derive from O
2
 and include the superoxide anion (O
2
•−), hydroxyl 
ion (OH), peroxyl (RO
2
), and alkoxy agents (RO•), as well as certain nonradicals that are either 
oxidizing or easily converted into radicals, such as hypochlorous acid (HOCl), ozone (O3), sin-
glet oxygen (1O
2
), and hydrogen peroxide (H
2
O
2
). There are other types of molecules that are oxi-
dizing agents but contain nitrogen; these radicals are called RNS. One example is peroxynitrite 
(NOO−), which is derived from nitric oxide (NO) when oxidized by O
2
•− [5]. These molecules 
are highly reactive due to the presence of an unpaired valence electron layer [6, 7], and through 
this electronic condition, ROSs avidly interact with a large number of molecules, including the 
plasma membrane and organic macromolecules such as proteins, lipids, carbohydrates, and 
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nucleic acids, to achieve electron stability. Through such interactions, ROS can irreversibly alter 
or destroy the function of specific molecules in the cell; for this reason, ROSs are recognized as 
important players in many cellular signaling and physiological processes [8].
Based on the above, ROSs are considered harmful molecules that promote cellular aging in bio-
logical organisms. However, to date, at least one beneficial function has been described: ROSs 
produced by leukocytes, neutrophils, and macrophages were found to play a major role in the 
defense against host molecules or foreign agents [9]. Additionally, ROSs were recently proposed 
to participate not only in cellular damage and the destruction of pathogens but also in several 
reversible regulatory processes in all cells and tissues [9]. In other words, in a healthy organ-
ism, the cell normally produces low levels of ROS, which activates specific signaling pathways 
that contribute to normal responses to various stimuli [10]; however, the inability to adequately 
compensate for an increase in ROS by the antioxidant system of the tissue or organism (known 
as “oxidative stress”) can result in the development of several pathologies [11].
Therefore, under oxidative stress, high levels of ROS produce changes in the cell through the 
following mechanisms: (1) activating redox-sensitive protein kinases, such as JAKs, PKC, PI3K, 
and PDK; (2) activating mitogen-activated protein kinase (MAPK) family members, such as 
Akt, JNKs, Erk1/2, and p38, which are involved in angiogenesis and cell proliferation, dif-
ferentiation, migration, growth, motility, survival, and apoptosis; (3) altering the activity of 
redox-sensitive transcription factors, such as AP-1, NF-κB, HIF-1α, and STAT; (4) inhibiting 
protein tyrosine phosphatase (PTP), which produces high levels of phosphorylated proteins; 
(5) producing an increase in the concentration of intracellular calcium [Ca2+]
I
; (6) producing 
direct effects on cellular structures, such as enzymes, receptors, and ion channels, or generat-
ing indirect effects on these structures through polyunsaturated fatty acids (PUFAs), which are 
highly susceptible to ROS, such that the oxidative breakdown of n-3 PUFAs may compromise 
membrane lipid matrix dynamics and, hence, the structure and function of membrane-associ-
ated proteins, such as enzymes, receptors, and transporters; and (7) stimulating the activity and 
expression of pro-inflammatory molecules and pro-oncogenes [1, 7, 8, 12–14].
For these reasons, regulating ROS production modulates the activity of various intracellular 
molecules and various cell signaling pathways, thereby inducing specific acute and chronic 
changes in the phenotype and function of a cell (commonly referred to as “redox signaling”). 
Thus, with a specific focus on the cardiovascular system, ROSs play an important physiologi-
cal role in the control of endothelial functions, vascular tone, and cardiac functions, as well as 
a pathophysiological role in inflammation, hypertrophy, fibrosis, angiogenesis, cell prolifera-
tion, apoptosis, and migration, whereby all these processes synergistically contribute to endo-
thelial dysfunction and cardiovascular remodeling [7], as we demonstrate later in this chapter.
2.2. High-altitude exposure: types of exposure and principal cardiovascular 
responses
As a result of decreased barometric pressure and oxygen partial pressure (PaO
2
), exposure to 
high altitudes generates an important effect on the cardiovascular system known as hypobaric 
hypoxia, where reduced uptake of oxygen leads to a decrease in O
2
 transported by the blood 
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to all the cells in the organism [15, 16]. The important physiological effects in living beings are 
derived from acclimatization or adaptability to high altitude, and these effects fundamentally 
depend on the level of altitude and the duration of exposure [3].
Acute hypoxia (AH) occurs when a person (e.g., a tourist or alpinist) is exposed to high altitudes 
for short periods of time (days or hours), whereas chronic hypoxia (CH) occurs when a person 
is permanently exposed to hypoxic conditions (i.e., living at high altitude). A new and distinct 
form of exposure has recently been shown to be different from all types of hypobaric hypoxia 
described to date and is related to mining exploitation, thus termed “Chilean mining model of 
chronic intermittent exposure to high altitude” [17]. This type of hypobaric hypoxia involves 
working over 3000 m above sea level in shifts (days of work at high altitude and days of rest 
at sea level) and maintaining this condition for years. It has been estimated that over 200,000 
people work under these conditions [18]. This biological condition is classified as chronic 
intermittent hypobaric hypoxia (CIHH).
There are many effects of high altitude that could ultimately lead to pathologies. However, the 
principal effects are an increase in hematocrit levels by accumulative red cell production or 
excessive erythrocytosis (chronic mountain sickness) and the development of acute mountain 
sickness (AMS), which can begin as mild to severe (as cerebral edema or lung edema). Another 
effect is the development of hypoxic pulmonary vasoconstriction (HPV), which leads to HAPH, 
with a prevalence of up to 15% in individuals exposed to high altitude [4].
The latter is of utmost interest, since its consequences are the clinical development of pulmonary 
hypertension and RVH or cor pulmonale [19–21]. Nevertheless, it must be noted that these effects 
appear to be less severe in CIHH exposure than in chronic exposure (CH) [16, 22].
3. ROS, hypoxia, and the cardiovascular system
3.1. The cardiovascular system and hypoxia-induced ROS
Previously, it was suggested that exposure to high altitude limits O
2
 supplementation in the 
organism in general and thus reduces the generation of free radicals (ROS), which are derived 
from this important gas [23]. However, this concept was later disputed with data suggesting that 
exposure to high altitude (>3000 m) leads to an increase in ROS production in many cell lines, 
thus generating an O
2
 supplementation paradox [24–26]. Finally, the high-altitude-induced 
increase in ROS products was confirmed by human studies, in which the concentrations of 
specific biomarkers of oxidative stress (plasmatic lipid peroxidation and iso-8-prostaglandin 
F-2α level in urine) were found to be increased after acute or chronic exposure to high altitude 
(4300 m) and without exercise [6]. Therefore, these findings suggest that exposure to hypoxia 
produces oxidative stress, thus causing all the aforementioned effects on both physiological 
and pathological cell signaling responses [9, 27].
Studies have evaluated the main sources of ROS in several cell lines under hypoxic conditions 
and concluded that the predominant source of ROS in the cardiovascular system is the enzymatic 
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complex nicotinamide adenine dinucleotide phosphate (NADPH) oxidase (NOX), which prevails over 
other ROS-generating systems, such as mitochondria and xanthine oxidase [5, 28]. NADPH oxi-
dases comprise a complex multicomponent family of transmembrane and cytosolic proteins 
that use NADPH as an electron donor to reduce molecular oxygen to the superoxide anion and 
hydrogen peroxide. The prototype NADPH oxidase was formerly known as gp91phox and was 
first described in leukocytes [1]. However, it is important to highlight that subsequent studies 
characterized seven members of the NOX family (NOX1 to 5 and dual oxidases 1 and 2) with 
diverse distributions among specific tissues and organs [10]; these NOX family members have 
since been described in nonphagocytic cells, including neurons, skeletal muscle, myocytes, hepa-
tocytes, endothelial cells, hematopoietic cells, stem cells, and cardiomyocytes [28]. For example, 
previous studies found that stimulating rat cardiomyocytes with angiotensin II (Ang II) directly 
activated the NADPH oxidase complex, specifically the NOX2 isoform. This NOX2 complex 
can be activated in healthy organisms by several factors, including a G-protein receptor agonist 
(Ang II) and endothelin-1 (ET-1), vascular endothelial growth factor (VEGF), and mechanical 
shear stress from blood flow. However, the pathological activation of NOX2 (e.g., cytokines such 
as tumor necrosis factor-alpha) can result in the generation of much higher concentrations of 
ROS that appear to contribute to pathological states, including endothelial dysfunction, myocar-
dial hypertrophy, fibrosis, heart failure, inflammation, atherosclerosis, coronary artery disease, 
stroke, and renal and pulmonary fibrosis [10].
Studies of the vascular system have shown that the predominant isoform of the NADPH complex 
is NOX4 [27, 29], and previous investigations revealed that NOX4 is involved in oxygen sensing, 
vasomotor control, angiogenesis, fibrosis, cell proliferation, differentiation, migration, apoptosis, 
and senescence. Elevated expression of NOX4 has been reported in a number of cardiovascular 
diseases, including atherosclerosis, pulmonary fibrosis, cardiac failure, and ischemic stroke [30].
Notably, previous studies have demonstrated that a single mutation in NOX4 disrupts O
2
•− 
production; these studies showed that although O
2
•− production was undetectable in NOX4-
transfected cells, there was robust production of H
2
O
2
, in contrast to the mixture of O
2
•− and 
H
2
O
2
 production following transfection with NOX1-NOX3 and NOX5 [31].
This effect of NOX4 was found due to the mutation of a highly conserved histidine residue in 
the E-loop of the NOX4 structure that promotes the rapid dismutation of O
2
•− before it leaves 
the enzyme [32], highlighting that higher concentrations of NOX4-produced H
2
O
2
 also elicit 
multiple effects. These effects are smooth muscle cell hypertrophy, activation of metallopro-
teases, and a low concentration of NOX4, which has been proposed as a cardiac protector 
[33]. Preliminary data from DNA microarray screens indicate that H
2
O
2
 causes a more than 
two-fold induction in the expression of nearly 100 genes, with a more than two-fold reduc-
tion in the expression of many more. Further, many transcription factors have been shown 
to be activated by H
2
O
2
. For example, as mentioned above, nuclear factor-κB (NF-κB) usually 
resides in the cytoplasm in association with an inhibitor protein (IκB) but is dissociated from 
IκB in the presence of H
2
O
2
. This process generates the nuclear translocation of NF-κB, and 
other transcription factors directly affected by exogenous H
2
O
2
, such as activator protein 1 
(AP-1) (a complex composed of the jun and fos gene products) [1].
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3.2. HAPH and NOX4-produced ROS
As mentioned previously, HAPH is one of the principal pathologies involved in hypoxic expo-
sure and arises from the narrowing of pulmonary arteries, which elevates pulmonary vascular 
resistance and, consequently, pulmonary artery pressure. HAPH is characterized by excessive 
proliferation and hypertrophy of pulmonary arterial medial smooth muscle and adventitial 
remodeling. ROS may serve as important regulators of pulmonary vascular remodeling, and 
some evidence supports a prominent role of NOX4 in the pathogenesis of HAPH [27]. For 
example, NOX4 is the major NADPH oxidase homolog expressed in human pulmonary artery 
smooth muscle cells, and its expression at both the mRNA and protein levels is significantly 
increased in lungs from patients with idiopathic pulmonary arterial hypertension (IPAH) 
compared to that in healthy lungs [34], which may suggest a strong correlation between NOX4 
and the onset of HAPH.
In addition, NOX4 expression was found to be increased in a CH-induced pulmonary artery 
hypertension (PAH) experimental mouse model. Therefore, NOX4 may also mediate hypoxia-
induced growth of human pulmonary smooth muscle cells [35]. Indeed, this was corroborated in 
studies that silenced NOX4 expression by RNA interference; the results demonstrated a decrease 
in the growth of human pulmonary arterial smooth muscle cells and fibroblast proliferation [30].
Furthermore, if we focus on the HPV response to high altitude (hypobaric hypoxia), this effect is 
explained by smooth muscle cell contraction. Studies have shown that one of the main pathways 
involves an increase in intracellular calcium [Ca2+]
I
 from the extracellular space and intracellu-
lar stores through voltage-activated potassium channels (KV) and nonspecific cation channels 
(NSCC) [36]. Nevertheless, further studies in lung cells found an increase in hypoxia-induced 
ROS that produced the activation of a calcium sensor (SMIT1) in the endoplasmic reticulum 
(ER), where this protein activates CRAC channels that contribute to the increase in intracellular 
Ca2+ [37].
In the nitric oxide (NO) pathway, studies have reported that intermittent hypobaric hypoxia 
exposure reduces the bioavailability of NO in lung parenchyma and vasculature [27, 38]. NO is 
an endogenous vasodilator that activates cyclic GMP, which in turn activates protein kinase G 
(PKG) and ultimately causes reuptake of Ca2+ and the opening of calcium-activated potassium 
channels, leading to the relaxation of vascular smooth muscle cells (VSMCs). The decrease in 
NO bioavailability observed following exposure to intermittent hypobaric hypoxia may be 
due to the destruction of NO by hypobaric hypoxia-induced ROS, such as superoxide anion 
(O2−), which is produced by the enzymatic complex NAPH oxidase, specifically the NOX4 
subunit [27, 29]. In agreement with these findings, studies silencing NOX4 and p22phox, 
another subunit involved in the activation of NADPH oxidase-NOX4, showed attenuation 
of ROS formation and proliferation in human and rat pulmonary artery smooth muscle cells 
(PASMCs) [39]. Therefore, all these ROS-activated cellular mechanisms may contribute to pul-
monary artery remodeling, pulmonary hypertension, and finally, cardiac failure due to RVH.
Recently, other studies noted that NOX4 does not contribute to the development of hypoxia-
induced pathologies, such as HPV or pulmonary hypertension. However, these studies found 
increases in superoxide anion (O
2
•−) levels in SMCs of NOX2- and NOX1-overexpressing mice 
and that NOX4 overexpression increased H
2
O
2
 levels. Therefore, NOX4 may be incapable of 
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destroying NO; this contrasts with NOX1- and NOX2-derived O
2
•−, which destroys NO and con-
tributes to the formation of ONOO−, thus leading to vascular dysfunction [40].
NOX4 has received considerable attention because it differs from NOX1 and NOX2 in several 
aspects: (1) NOX4 mRNA expression is higher than that of the other NOX homologs (>1000-
fold higher copy number than NOX1 and NOX2) and different from NOX1 and NOX2, which 
are induced by Ang II in VSMCs. This is supported by studies in cultured cells showing the 
expression of NOX4 mRNA at copy numbers greater than 10- to 100-fold that of NOX2 and 
greater than 100-fold that of NOX1 [41]. Therefore, NOX4 is the most abundant NOX isoform 
in the vasculature. However, one must be mindful that mRNA levels may not accurately reflect 
protein expression levels of the various NOX isoforms [42]. (2) NOX4 expression increases over 
the course of differentiation and is required for the maintenance of the differentiated pheno-
type in cultured cells. (3) NOX4, unlike NOX1 and NOX2, is independent of cytosolic activa-
tor subunits and thus is potentially constitutively active. This is supported by overexpression 
studies conducted mostly in HEK293 cells, which have suggested that NOX4-dependent ROS 
production is controlled by the abundance of the enzyme. This aspect does not exclude the 
possibility that other interacting proteins, such as Poldip2 or protein disulfide isomerase, alter 
the activity of NOX4. Conversely, NOX4 predominantly releases H
2
O
2
, which cannot alter 
NO. NOX4 overexpression in the presence of NO does not lead to ONOO− formation, which 
strongly argues against significant O
2
•− formation by the enzyme [33].
Therefore, eNOS uncoupling is an important mechanism that leads to endothelial dysfunction. 
It is becoming progressively clear that the presence of low concentrations of H
2
O
2
 not only acts 
as a vasodilator by activating kinase G Iα3 but also may activate and induce eNOS by several 
mechanisms [33]. Thus, NOX4 might have an antagonistic function to NOX1 and NOX2, since 
it differs from these NADPH oxidases. NOX4 is a special NOX because it is highly constitu-
tively active and is highly expressed in many cardiovascular cells. However, studies using both 
anti-NOX4 antibodies and in situ hybridization showed that NOX4 is primarily expressed in 
the middle layer of pulmonary blood vessels in both mice and humans [34].
Numerous studies have shown that NOX4 is robustly upregulated in response to transform-
ing growth factor-beta (TGF-β) stimulation in various cell types, including aortic and pulmo-
nary smooth muscle cells, pulmonary and cardiac fibroblasts, and endothelial and embryonic 
kidney cells [43]. However, tumor necrosis factor-alpha is less specific and can increase 
NOX1, NOX2, and NOX4 activity and/or the expression of these oxidases in various vascular 
cells. Other stimuli that induce NOX4 expression are ER stress, shear stress, hypoxia, and 
ischemia, as well as the activation of PKCα, NF-κB, HIF-1α, and Nrf2. These pathways are 
also likely dependent on the stimulus and cell type [44], and as mentioned above, Ang II has 
been shown to potently activate NOX1 and NOX2, but its effect on NOX4 expression is much 
less pronounced [30].
3.3. Cardiac myocytes and HIF-1α
HIF-1α is a heterodimeric subunit of the transcription factor HIF-1, which regulates the tran-
scription of genes involved in adaptive responses to hypoxia. Therefore, HIF-1 induces and pro-
motes the expression of several genes containing hypoxia-responsive elements (HREs) in their 
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regulatory region, such as proangiogenic factors (VEGF) or stromal-cell derived factor-1α (SDF-1α, 
CXCL12), vasoconstrictors (endothelin-1), and inflammation-associated genes (iNOS—inducible 
nitric oxide synthase and COX2—cyclooxygenase). Many of these factors promote angiogenesis 
and wound healing and are thus critical for the response to local hypoxia and injury. This HIF-1 
system is also used to measure the systemic oxygen supply and to control the formation of red 
blood cells [12] through the glycoprotein erythropoietin (EPO). EPO has strong organ-protective 
effects in the heart, brain, and kidney, promotes re-endothelialization, and induces the mobili-
zation of endothelial progenitor cells (EPCs), where ROS-NOX2 production is fundamental for 
EPO-induced mobilization of EPCs and vascular repair in hypoxic conditions [12].
However, the role of HIF-1α in the development of cardiac hypertrophy has been sparsely doc-
umented [45]. More interestingly, carvedilol, a β-receptor blocker, has emerged as a beneficial 
treatment for cardiac hypertrophy, as it inhibits the overexpression of HIF-1α during pressure 
overload in the rat heart [46]. Subsequent studies in cardiomyocytes under mild hypoxic condi-
tions showed that HIF-1α controls the process of cardiac hypertrophy through the activation of 
transient receptor potential canonical 3 (TRPC3) and 6 (TRPC6), producing an increase in the 
levels of [Ca2+]
i
 and calcineurin [47].
TRPC channels are nonselective cation channels that mediate Ca2+ influx into several cell types, 
including cardiac myocytes [48]. TRPC expression in cardiac hypertrophy has been studied 
by several laboratories, with somewhat variable results. For example, previous studies have 
shown that TRPC3 promotes cardiomyocyte hypertrophy in several animal models, includ-
ing abdominal aortic banding (AAB) rats and spontaneous hypertensive heart failure rats 
[47]. Other studies have demonstrated that TRPC6 sequentially initiates a calcineurin signal-
ing circuit during pathological cardiac hypertrophy. However, Ohba et al. [49] demonstrated 
that TRPC1, TRPC3, TRPC5, and TRPC6 are constitutively expressed, but only TRPC1 expres-
sion is significantly increased in hypertrophic hearts from AAB rats. However, these studies 
regarding the role of HIF-1α in cardiac hypertrophy were based on pathological situations, 
and their conclusions were controversial. Therefore, the potential role of HIF-1α in adaptive 
cardiac hypertrophy needs to be clarified.
Further, previous studies showed that the HIF-1 pathway is involved in hypoxia-induced 
autophagy in cardiomyocytes and that HIF-1-induced autophagy may, therefore, help cardio-
myocytes to overcome hypoxic injury and increase survival [50]. In other words, HIF-1α upreg-
ulation can increase autophagy and ameliorate the hypoxia-induced reduction in cell viability. 
Regarding survival and cardiac viability in hypoxic conditions, cardiac muscle cell survival 
plays a critical role in maintaining the correct function of the heart and, possibly, in cardiac 
embryogenic development. In contrast, adult cardiomyocytes are thought to be terminally dif-
ferentiated and therefore have lost their proliferative capacity. One of the mechanisms that 
cardiomyocytes employ to protect themselves from deleterious stimuli is the release of survival 
cytokines capable of promoting cytoprotection in an autocrine/paracrine manner [51, 52]. One 
of these cytokines is cardiotrophin-1 (CT-1). CT-1 is a member of the interleukin-6 family with 
hypertrophic properties in neonatal and adult cardiomyocytes [53]. In adult cardiomyocytes, 
CT-1 exerts a protective function in response to death stimuli (apoptosis and necrosis), such as 
Ang II, H
2
O
2
, and ischemia-reperfusion. The cardioprotective properties of CT-1 under stress 
conditions suggest that it may be upregulated during cardiac diseases that are characterized by 
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an environment of reduced oxygen availability, inflammation, and oxidative stress. Indeed, cir-
culatory levels of CT-1 are elevated in pathological conditions associated with ischemia, includ-
ing unstable angina pectoris, acute myocardial infarction, hypertensive heart disease, and heart 
failure. Importantly, studies have shown that hypoxia increased CT-1 in cardiac cells (in vitro 
and in vivo) through direct regulation of the CTF1 promoter by HIF-1α, and this CT-1 activation 
may protect cells from apoptosis, thus supporting a protective role of CT-1 as a survival factor 
for cardiomyocytes [52].
3.4. Myocardium, myocytes, and hypoxia-induced ROS
HAPH-induced RVH or end-stage cor pulmonale [19–21] is primarily explained as a compen-
satory effect of right ventricular afterload. However, numerous investigations have established 
new avenues for the development of cardiac hypertrophy that highlight oxidative stress as the 
main mediator [5, 54].
To support the involvement of oxidative stress, a study evaluating both smooth muscle cells 
and endothelial cells in the development of pulmonary artery remodeling in CH was con-
ducted. This study found that such arterial remodeling occurs via a mitochondrial factor, which 
requires the Rieske iron-sulfur protein (RISP), a mitochondrial complex III protein required 
for ROS generation. RISP depletion in endothelial cells and smooth muscle cells prevented 
CH-induced pulmonary hypertension, but it did not prevent RVH, suggesting that right ventri-
cle remodeling in CH occurs through a mechanism independent of the increase in pulmonary 
artery pressure [55]. Thus, RVH could be directly produced by hypoxia-induced ROS, such that 
some in vitro experiments showed increased ROS levels in chicken cardiomyocytes and Hep3B 
cells cultured under AH [56].
Therefore, acute and chronic hypoxic exposure could generate oxidative stress [6] and may 
activate a large variety of protein kinases, such as MAPK, tyrosine kinases, and Rho kinases, 
and transcription factors (NF-κB, AP-1, and HIF-1α) that are derived from cellular hypertrophy 
[57] may also inactivate PTP. Both combined and separate effects induce an increase in the phos-
phorylation cascade or produce an increase in the concentration of intracellular calcium [Ca2+]
I
 
and stimulate the activity and expression of pro-inflammatory genes and proto-oncogenes [7].
Regarding cardiomyocytes, NOX2-mediated O
2
•− formation has been found to activate the pro-
tein kinase B or serine/threonine kinase (Akt) signaling pathways through PI3K, JNK, ERK1/2, 
and p38-MAPK. Thus, activation of these signaling pathways may play a central role in Ang 
II-stimulated cardiomyocyte hypertrophy [5, 58, 59]. Consequently, oxidative stress could 
play a fundamental role in cardiac hypertrophy, specifically RVH (possibly independent of 
the mechanical explanation) as a result of exposure to hypoxia. This is congruent with other 
studies demonstrated that NOX2 knockout attenuated Ang II and myocardial infarct-induced 
myocardial fibrosis and cardiomyocyte hypertrophy in mice. Hence, it could be surmised that 
NOX2 may play an important role in the development of cardiac hypertrophy in either hypoxic 
or other conditions, and this role may be independent of changes in blood pressure [60].
In addition to NOX2, several studies have reported a relative abundance of NOX4 expression 
in human and mouse cardiac myocytes [61, 62] and in pulmonary arteries under hypoxia [27]. 
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NOX4 is induced in experimental models of heart failure and in humans [61]. Recent studies 
using cardiac-specific NOX4 knockout mice revealed decreased levels of ROS and improved 
performance along with reduced hypertrophy, fibrosis, and apoptosis. Conversely, an experi-
ment using a transgenic cardiac-specific NOX4-overexpressing mouse showed deleterious 
effects, such as promoting dysfunction, fibrosis, and apoptosis, in response to pressure over-
load [62]. While these results suggest that NOX4 is a major source of oxidative stress involved 
in the failing heart, there are reports showing opposite effects using a global NOX4 knock-
out and cardiac-specific NOX4 transgenic model [63]. These contradictory findings could be 
explained by differences in the methodology used to induce heart failure.
Supporting a more active role of NOX4, studies have revealed that NOX4 induces positive 
endothelial effects by producing H
2
O
2
, which in turn activates protein kinase G Iα by thiol oxi-
dation and subsequent dimerization. Moreover, H
2
O
2
 also activates endothelial NOS (eNOS). 
Therefore, it is necessary to determine how NOX4 may mediate such contradictory roles [30].
Another important source of ROS in cardiomyocytes is the mitochondrial complex (electron 
transport chain). Previous studies have found that mitochondria in cardiomyocytes increase 
their generation of ROS during hypoxia (1–5% O
2
), with the increased ROS generation origi-
nating from the proximal region of the electron transport chain, most likely complex III. These 
observations suggest that ROS generated by mitochondria may trigger p38 phosphorylation 
(activation) during hypoxia and thus highlight that the role of p38 phosphorylation in cardio-
myocytes is highly dependent on PO
2
. Moreover, this ROS-induced p38 activation has been 
shown through another source independent of the electron transport chain, cobalt chloride 
[64]. However, hemoglobin (Hb), which is increased in hypobaric hypoxia exposure, depend-
ing on the type and duration of exposure, has intrinsic heme-oxidase activity that leads to the 
production of superoxide and thus contributes to oxidative stress. Therefore, the release of 
superoxide by Hb is favored in the T structure. Thus, sustained or excessive desaturation of 
Hb (T structure) may increase ROS production [65], and the phosphorylation of p38 MAPK 
during hypoxia may involve several ROS sources.
Although ROS generation is a normal physiological process, its counterbalance seems to be 
impaired under hypobaric hypoxia. The resulting imbalance leads to changes with potential 
pathological consequences for the cardiovascular system.
4. Conclusion
Under hypobaric hypoxia, ROS levels are elevated, resulting in a subsequent unbalanced oxi-
dative status. The principal sources of hypobaric hypoxia are NOX4 in the vascular system and 
NOX2 in cardiac tissue. The main effects of this oxidative increase include cellular damage, 
impaired NO pathway signaling, and the activation of calcium channels, transcription factors, 
pro-inflammatory molecules, and kinase proteins, all of which have deleterious effects on the 
cardiovascular system.
Therefore, this exaggerated or unbalanced ROS activity is closely related to the development of 
specific changes in the cardiovascular system under hypoxia, such as HPV, altitude pulmonary 
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hypertension, pulmonary artery remodeling, and RVH. Notably, although most of the sources 
in this review described results from nonhypobaric hypoxia conditions, the information gath-
ered reveals a broad view of the relationship between ROS and hypoxia. However, it is still 
necessary to further elucidate the undefined aspects of this association and the controversies 
concerning the poor characterization of hypobaric hypoxia.
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